Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter’s War Games: Post-Heparin, Scientists Consider Supply Chain Threats

Executive Summary

Part of Baxter's response to its heparin contamination fiasco has been to bring its scientists together to imagine ways counterfeiters could infiltrate its supply chain and how they would be countered

You may also be interested in...



GMP Warnings Split Between Brand, Generic Firms; Congress Watches FDA

The number of prescription drug manufacturing warning letters from FDA remained roughly split between brands and generics during the last year, but brands dominated the citations in early 2008, in contrast to generics' dominance since mid-year, when the House Energy and Commerce Committee launched an investigation into the agency's handling of products produced by Ranbaxy

GMP Warnings Split Between Brand, Generic Firms; Congress Watches FDA

The number of prescription drug manufacturing warning letters from FDA remained roughly split between brands and generics during the last year, but brands dominated the citations in early 2008, in contrast to generics' dominance since mid-year, when the House Energy and Commerce Committee launched an investigation into the agency's handling of products produced by Ranbaxy

Dingell May Tighten Inspection Provisions In Safety Bill, After Ranbaxy Alert

House Energy and Commerce Committee Chairman John Dingell, D-Mich., is likely to strengthen FDA mandates proposed in his evolving global drug safety bill, in light of the new Import Alert for more than three dozen Ranbaxy products

Related Content

UsernamePublicRestriction

Register

PS049606

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel